Haplotype frequency distribution and linkage disequilibrium analysis of single nucleotide polymorphisms at the human FMO3 gene locus

被引:9
作者
Hao, Da-Cheng
Sun, Jie
Furnes, Bjarte
Schlenk, Daniel
Hou, Zhen-Fang
Zhang, Ya-Ping
Yang, Sheng-Li
Yang, Ling [1 ]
机构
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut Resource Discovery, Dalian, Peoples R China
[2] Dalian Med Univ, Dept Emergency Med, Dalian, Peoples R China
[3] Univ Calif Riverside, Environm Toxicol Program, Riverside, CA 92521 USA
[4] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China
[5] Chinese Acad Sci, Kunming Inst Zool, Lab Cellular & Mol Evolut, Kunming, Peoples R China
关键词
FMO3; polymorphism; haplotype frequency; linkage; evolution;
D O I
10.1007/s10528-006-9037-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We analyzed flavin-containing monooxygenase 3 (FMO3) polymorphisms, haplotype structure, and linkage disequilibrium (LD) in 256 Han Chinese and 50 African-American individuals to compare their haplotype frequencies and LD with other world populations. For the Han Chinese, genotyping of three haplotype tag single nucleotide polymorphisms (E158K, V257M, and E308G) was performed by polymerase chain reaction (PCR)-restriction fragment length polymorphism. For the African-Americans, genotyping of all coding exons was performed by modified PCR-single strand conformational polymorphism. Haplotype frequencies, LD, and evolutionary rates were inferred and estimated computationally. There were significant differences in haplotype frequency distribution and LD pattern among Han Chinese, African-Americans, and other world populations. Four major haplotypes of Han Chinese were EVE, KVE, EME, and EVG. Two major haplotypes of African-Americans were EVE and KVE. We found that sites 158 and 257 are in significant LD in both populations. This is the first report comparing FMO haplotypes and LD of Han Chinese with African-Americans. The data presented here justify further pharmacogenetic studies for potentially optimizing recommended drug dosages and evaluating relationships with disease processes.
引用
收藏
页码:391 / 407
页数:17
相关论文
共 25 条
[1]   Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism [J].
Cashman, JR .
PHARMACOGENOMICS, 2002, 3 (03) :325-339
[2]  
Cashman JR, 2001, DRUG METAB DISPOS, V29, P1629
[3]  
Cashman JR, 2000, DRUG METAB DISPOS, V28, P169
[4]   The implications of polymorphisms in mammalian flavin-containing monoloxygenases in drug discovery and development [J].
Cashman, JR .
DRUG DISCOVERY TODAY, 2004, 9 (13) :574-581
[5]   Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: Determination by caffeine metabolism [J].
Chung, WG ;
Kang, JH ;
Park, CS ;
Cho, MH ;
Cha, YN .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (03) :258-266
[6]   Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans [J].
Furnes, B ;
Feng, JN ;
Sommer, SS ;
Schlenk, D .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (02) :187-193
[7]   Trimethylaminuria and a human FMO3 mutation database [J].
Hernandez, D ;
Addou, S ;
Lee, D ;
Orengo, C ;
Shephard, EA ;
Phillips, IR .
HUMAN MUTATION, 2003, 22 (03) :209-213
[8]   Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters [J].
Hernandez, D ;
Janmohamed, A ;
Chandan, P ;
Phillips, IR ;
Shephard, EA .
PHARMACOGENETICS, 2004, 14 (02) :117-130
[9]   Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis [J].
Hisamuddin, IM ;
Wehbi, MA ;
Schmotzer, B ;
Easley, KA ;
Hylind, LM ;
Giardiello, FM ;
Yang, VW .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (10) :2366-2369
[10]   Genetic polymorphisms of human Flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis [J].
Hisamuddin, IM ;
Wehbi, MA ;
Chao, A ;
Wyre, HW ;
Hylind, LM ;
Giardiello, FM ;
Yang, VW .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8357-8362